Dexcom earnings date, guidance and results
MyStockButler's October 2026 analysis: Dexcom reports third-quarter results on October 29, 2026. Watch whether demand, margins and cash flow advance together.
What has Dexcom guided for 2026?
Management raised its 2026 outlook on July 30 and set a longer plan at its May 14 investor day. The plan calls for at least 10.0% organic revenue growth each year through 2030 and a 29.0%–30.0% non-GAAP operating margin in 2030. “Organic” means growth from the underlying business, excluding currency effects and certain portfolio changes.
| Period guided | Low | High | Date given | |
|---|---|---|---|---|
| Revenue | Year to Dec 2026 | 5.18 | 5.25 | Jul 30, 2026 |
| Revenue growth | Year to Dec 2026 | 11.0% | 13.0% | Jul 30, 2026 |
| Non-GAAP Gross Profit Margin | Year to Dec 2026 | 64.0% | 64.0% | Jul 30, 2026 |
| Non-GAAP Operating Margin | Year to Dec 2026 | 23.5% | 24.0% | Jul 30, 2026 |
| Adjusted EBITDA Margin | Year to Dec 2026 | 31.5% | 32.0% | Jul 30, 2026 |
| Organic Revenue growth | Each year through Dec 2030 | 10.0% | May 14, 2026 |
What this means. Organic revenue growth excludes currency changes and acquired or sold businesses, so it can differ from the growth rate calculated from the company's reported sales.
Has Dexcom kept its promises?
Dexcom’s promise-keeping record earns 3/5. Revenue beat its initial range three times, landed within it once and fell below it once. Gross-margin promises fell short three times, while operating-margin promises fell short twice. Damaged inventory, production settings and supply costs contributed to the misses. The long-range plan therefore depends on dependable manufacturing, not only demand.
| What management forecast | Checked | Above | Within | Below |
|---|---|---|---|---|
| Revenue | 5 years | 3 | 1 | 1 |
| Non-GAAP Gross Profit Margin | 5 years | 2 | 0 | 3 |
| Non-GAAP Operating Margin | 5 years | 3 | 0 | 2 |
What this means. The revenue forecast is shown in billions of United States dollars, while the other money figures are shown in millions, so the units are different.
What do Dexcom's last eight quarters show?
Margins provide stronger evidence. Gross margin improved from 59.5% to 63.4%, and operating income rose from $212.6 million to $318.3 million. The improvement continued across several quarters, which makes it more persuasive than a single isolated result. Management attributed it to manufacturing and quality efficiencies, the initial G7 15 Day conversion and more efficient shipping.
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,308.4 | 1,191.9 | 1,259.6 | 1,209.3 | 1,157.1 | 1,036.0 | 1,113.5 | 994.2 |
| Gross margin | 63.4% | 62.9% | 62.9% | 60.5% | 59.5% | 56.9% | 58.9% | 59.7% |
| Operating income | 318.3 | 255.3 | 323.0 | 242.5 | 212.6 | 133.7 | 188.9 | 152.0 |
| Net income | 249.1 | 199.5 | 267.3 | 283.8 | 179.8 | 105.4 | 151.7 | 134.6 |
| EPS, diluted | 0.64 | 0.51 | 0.68 | 0.70 | 0.45 | 0.27 | 0.38 | 0.34 |
| = Free cash flow | 184.5 | 449.0 | 192.1 | 579.4 | 208.9 | 96.8 | 176.8 | 88.3 |
What this means. Each column covers one quarter, or about three months, even though some descriptions say “year.”
What should I watch in Dexcom's next results?
Dexcom reports third-quarter results on October 29, 2026. Revenue will test demand against the raised outlook. Margins will show whether earlier improvement survives the Irish hiring period, while cash flow will show how much reported profit became deployable money.